1. Home
  2. NMRA vs LEGT Comparison

NMRA vs LEGT Comparison

Compare NMRA & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • LEGT
  • Stock Information
  • Founded
  • NMRA 2019
  • LEGT 2023
  • Country
  • NMRA United States
  • LEGT United States
  • Employees
  • NMRA N/A
  • LEGT N/A
  • Industry
  • NMRA
  • LEGT
  • Sector
  • NMRA
  • LEGT
  • Exchange
  • NMRA Nasdaq
  • LEGT Nasdaq
  • Market Cap
  • NMRA 121.0M
  • LEGT 274.3M
  • IPO Year
  • NMRA 2023
  • LEGT 2024
  • Fundamental
  • Price
  • NMRA $1.27
  • LEGT $10.71
  • Analyst Decision
  • NMRA Buy
  • LEGT
  • Analyst Count
  • NMRA 8
  • LEGT 0
  • Target Price
  • NMRA $9.29
  • LEGT N/A
  • AVG Volume (30 Days)
  • NMRA 1.7M
  • LEGT 19.5K
  • Earning Date
  • NMRA 08-05-2025
  • LEGT 01-01-0001
  • Dividend Yield
  • NMRA N/A
  • LEGT N/A
  • EPS Growth
  • NMRA N/A
  • LEGT N/A
  • EPS
  • NMRA N/A
  • LEGT 0.35
  • Revenue
  • NMRA N/A
  • LEGT N/A
  • Revenue This Year
  • NMRA N/A
  • LEGT N/A
  • Revenue Next Year
  • NMRA N/A
  • LEGT N/A
  • P/E Ratio
  • NMRA N/A
  • LEGT $0.91
  • Revenue Growth
  • NMRA N/A
  • LEGT N/A
  • 52 Week Low
  • NMRA $0.61
  • LEGT $10.11
  • 52 Week High
  • NMRA $17.19
  • LEGT $10.86
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 76.17
  • LEGT N/A
  • Support Level
  • NMRA $0.72
  • LEGT N/A
  • Resistance Level
  • NMRA $1.41
  • LEGT N/A
  • Average True Range (ATR)
  • NMRA 0.13
  • LEGT 0.00
  • MACD
  • NMRA 0.05
  • LEGT 0.00
  • Stochastic Oscillator
  • NMRA 79.83
  • LEGT 0.00

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

About LEGT Legato Merger Corp. III

Legato Merger Corp III is a blank check company.

Share on Social Networks: